Bounhiol Agathe, Pasquier Grégoire, Novara Ana, Bougnoux Marie-Elisabeth, Dannaoui Eric
Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, AP-HP, European Georges-Pompidou Hospital, 75015 Paris, France.
Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, Necker-Enfants Maladies Hospital, 75015 Paris, France.
J Mycol Med. 2022 Aug;32(3):101290. doi: 10.1016/j.mycmed.2022.101290. Epub 2022 Apr 27.
It is now well known that patients with severe COVID-19 are at risk for developing invasive pulmonary aspergillosis (IPA). Nevertheless, the symptomatology of IPA is often atypical in mechanically ventilated patients and the radiological aspects of SARS CoV-2 pneumonia and IPA are difficult to differentiate. In this context, the significance of the presence of Aspergillus in respiratory tract samples (detected by culture, galactomannan antigen, or specific PCR) is not yet fully understood. Here we report two cases of intubated and mechanically ventilated ICU patients with SARS-CoV-2 pneumonia, in whom Aspergillus was detected in respiratory samples, who had a favorable outcome in the absence of antifungal treatment. These two cases highlight the difficulty of using the new definitions of COVID-19 associated pulmonary aspergillosis for routine management of patients.
目前众所周知,重症新型冠状病毒肺炎(COVID-19)患者有发生侵袭性肺曲霉病(IPA)的风险。然而,IPA的症状在机械通气患者中通常不典型,且严重急性呼吸综合征冠状病毒2(SARS-CoV-2)肺炎和IPA的影像学表现难以区分。在此背景下,呼吸道样本中曲霉菌的存在(通过培养、半乳甘露聚糖抗原或特异性聚合酶链反应检测)的意义尚未完全明确。我们在此报告两例插管并接受机械通气的重症监护病房(ICU)患者,他们患有SARS-CoV-2肺炎,呼吸道样本中检测到曲霉菌,在未接受抗真菌治疗的情况下预后良好。这两例病例凸显了将COVID-19相关肺曲霉病的新定义用于患者常规管理的困难。